IFNβ therapy, an approach for clinical care of multiple sclerosis patients, impairs glucose tolerance and insulin sensitivity17 and is associated with hepatic dysfunction18,41, hinting at its impact on metabolic derangement. Here, IFNB1 is linked to multiple sclerosis.